Bolt Biotherapeutics Inc. (BOLT)
0.48
0.00 (0.21%)
At close: Feb 28, 2025, 3:59 PM
0.47
-0.75%
After-hours: Feb 28, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 0.46 |
| Market Cap | 18.3M |
| Revenue (ttm) | 9.78M |
| Net Income (ttm) | -65.12M |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | -0.56 |
| Analyst | Hold |
| Ask | 0.48 |
| Volume | 24,736 |
| Avg. Volume (20D) | 155,895 |
| Open | 0.48 |
| Previous Close | 0.48 |
| Day's Range | 0.46 - 0.48 |
| 52-Week Range | 0.46 - 1.56 |
| Beta | 0.95 |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for col...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 100
Stock Exchange NASDAQ
Ticker Symbol BOLT
Website https://www.boltbio.com
Analyst Forecast
According to 5 analyst ratings, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 161.45% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Bolt Biotherapeutics Inc. is scheduled to release its earnings on Mar 20, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
-37.12%
Bolt Biotherapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
9 months ago
-0.75%
Bolt Biotherapeutics shares are trading lower. The company reported Q1 financial results.
